menu
    • menu
    [{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C TGRX-326","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C TGRX-678","moa":"BCR-ABL|BCR-ABL T315I","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-1942","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Peking University People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Peking University People's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ Peking University People's Hospital"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-814","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China"}]

    Find Clinical Drug Pipeline Developments & Deals by Shenzhen TargetRx

    Menu

    Shenzhen TargetRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C TGRX-678

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-678 Pharmacokinetic Mass Balance

                            Details : 14-C TGRX-678 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 23, 2025

                            Lead Product(s) : 14-C TGRX-678

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-678 Phase I Oral Pharmacokinetic Study

                            Details : TGRX-678 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 20, 2024

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Simcere Zaiming

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Simcere Zaiming Collaborates with TargetRx to Introduce a Third-Generation ALK inhibitor

                            Details : Simcere Zaiming will acquire exclusive commercial rights to TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), in Mainland China.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $20.0 million

                            September 02, 2024

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Simcere Zaiming

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGRX-1942

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sir Run Run Shaw Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

                            Details : TGRX-1942 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : TGRX-1942

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sir Run Run Shaw Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

                            Details : TGRX-678 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 12, 2024

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C TGRX-326

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-326 Pharmacokinetic Mass Balance

                            Details : 14-C TGRX-326 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 31, 2024

                            Lead Product(s) : 14-C TGRX-326

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of Bengbu Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-326 Pharmacokinetic Food Effect Bioavailability Study

                            Details : TGRX-326 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : Deulorlatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of Bengbu Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-326 Pharmacokinetic Drug Interaction

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGRX-814

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

                            Details : TGRX-814 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hematologic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : TGRX-814

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

                            Details : TGRX-678 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : TGRX-678

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth